Home・Akcijų sąrašas・Royalty Pharma PLC (Class A)

Royalty Pharma PLC (Class A)

Uždarymo kaina

SektoriusSveikatos priežiūra

58.55 -1.1

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

57.86

Max

59.54

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-589M -295M
Pardavimai	44M 674M
P/E Sektoriaus vid.	30.511 57.002
Pelnas, tenkantis vienai akcijai	1.32
Dividendų pajamingumas	1.6
Pelno marža	-43.713
Darbuotojai	100
EBITDA	-387M 176M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+10.89% upside

Dividendai
By Acuity
Dividendų pajamingumas Sektoriaus vid.	1.60% 2.22%
Kitas uždarbis	2026-11-04
Kitas dividendų mokėjimo data	2026-09-10
Kita Ex Dividend data	2026-08-14

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	577M 33B
Ankstesnė atidarymo kaina	59.65
Ankstesnė uždarymo kaina	58.55

Royalty Pharma PLC (Class A) Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-13 20:02; UTC

Social Media

Royalty Pharma PLC shares are lower amid a $100 million royalty agreement with Zealand Pharma for rusfertide rights, reflecting unusual trading activity.

2026-08-12 20:01; UTC

Royalty Pharma PLC shares are higher today, supported by a broader market trend of gains since Tuesday. The stock is seeing unusually high trading volume.

2026-08-11 19:56; UTC

Royalty Pharma PLC shares are trading higher, reaching a session high earlier today. No specific news was identified to explain the price movement.

2026-08-10 23:16; UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting notable strength and unusual activity since Monday's close, with no specific news identified.

2026-08-07 23:41; UTC

Royalty Pharma PLC shares are higher in after-market hours, reflecting notable gains since Friday's close amid a shift toward a dovish monetary policy outlook.

2026-08-06 23:01; UTC

Royalty Pharma PLC shares are higher in after-market trading, moving above Thursday's close, despite remaining below the 20-day moving average.

2026-08-05 19:31; UTC

News

Royalty Pharma PLC raised its full-year guidance for Portfolio Receipts to $3.4 billion to $3.5 billion, contributing to a higher trading session.

2026-08-04 19:26; UTC

Royalty Pharma PLC shares are higher today, rebounding after earlier pulling back from a session high. The stock has fluctuated within a routine range.

2026-08-03 23:46; UTC

Royalty Pharma PLC shares are near unchanged in after-market trading, reflecting minimal movement since Monday's close and remaining below the 20-day moving average.

2026-08-01 00:03; UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a decline over the past four sessions. No specific news was identified to explain the move.

2026-07-31 23:01; UTC

Royalty Pharma PLC shares are lower in after-market hours, reflecting broader market trends despite some gains in mega-cap stocks. The stock remains below its 20-day moving average.

2026-07-30 22:01; UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting strong demand and trading above its 20-day moving average. No specific news was identified.

2026-07-29 19:27; UTC

Royalty Pharma PLC shares are lower today, reflecting a pullback since Tuesday's close amid rising oil prices and inflation concerns.

2026-07-28 23:46; UTC

Royalty Pharma PLC shares are lower in after-market trading, reflecting broader market declines amid concerns over technology sector dynamics.

2026-07-27 16:46; UTC

Royalty Pharma PLC shares are advancing during Monday's session. Broader market gains are supported by a notable decline in oil prices amid easing geopolitical tensions.

2026-07-24 22:21; UTC

In after-market trading, Royalty Pharma PLC is trading higher, nearing the upper end of its one-month range after recovering from an early low.

2026-07-22 19:11; UTC

News

Event

Royalty Pharma acquires a royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront payment. Shares are trading roughly flat.

2026-07-21 17:51; UTC

Royalty Pharma PLC shares are higher today, tracking broader market gains, with unusually high trading volume noted. No specific news was identified for the movement.

2026-07-20 19:21; UTC

Royalty Pharma PLC shares are lower as the Pharmaceuticals sector faces downward pressure, with unusually high trading volume noted today.

Akcijų palyginimas

Kainos pokytis

Royalty Pharma PLC (Class A) Prognozė

Kainos tikslas

By TipRanks

10.89% į viršų

12 mėnesių prognozė

Vidutinis 65.67 USD 10.89%

Aukščiausias 70 USD

Žemiausias 62 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Royalty Pharma PLC (Class A) kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių Royalty Pharma PLC (Class A) akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.